High-Dose Vitamin D3 Supplementation in Children and Young Adults with HIV: A Randomized, Placebo-Controlled Trial.
Pediatr Infect Dis J. 2014 Jul 1.
Stallings VA1, Schall JI, Hediger ML, Zemel BS, Tuluc F, Dougherty KA, Samuel JL, Rutstein RM.
BACKGROUND:
Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity. We aimed to determine 12-mo safety and efficacy of daily 7000IU vitamin D3 (vitD3) vs placebo to sustain increased serum 25-hydroxyvitamin D (25(OH)D) and improve immune status in HIV-infected subjects.
METHODS:
This was a double-blind trial of perinatally- (PHIV) or behaviorally-acquired (BHIV) HIV-infected subjects (5.0-24.9y). Safety, 25(OH)D-related parameters, and immune status were assessed at baseline, 3, 6, and 12 months.
RESULTS:
Fifty-eight subjects enrolled (67% male, 85% African-American, 64% BHIV) and 50 completed with no safety concerns. In unadjusted analyses, there were no differences between randomization groups at baseline; at 3, 6, and 12 months, 25(OH)D was higher with supplementation than baseline and higher than with placebo (P<0.05).
In adjusted mixed models, in the supplementation group, the fixed effect of 25(OH)D was higher (P<0.001).
- Percentage of naïve T helper cells (Th naïve%) were significantly (P<0.01) and
- T helper cells (CD4%) marginally (P<0.10) increased
with supplementation in those taking highly active antiretroviral therapy (HAART), and RNA viral load was reduced (P≤0.05). In exploratory linear models, change in 25(OH)D predicted RNA viral load at 3 and 12 months and CD4% at 3 months (P<0.05).
CONCLUSIONS:
Daily 7000IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25(OH)D. Supplementation improved in some clinically important HIV immune markers in subjects on HAART. Adjunct therapy with high-dose, daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation.
VitaminDWiki – HIV category contains:
Pregnant women in HIV therapy adding Vitamin D had 3X fewer deaths - RCT April 2022
HIV treatment augmented by high-dose vitamin D, daily or weekly – Dec 2021
Low vitamin D with HIV increases risk of infections – TB by 3.5X, CMV by 10.1X – Aug 2020
HIV therapy reduces Vitamin D levels, supplementation helps - Nov 2019
Cognitive problems 2X more likely if HIV and low vitamin D – June 2019
Use of Tenofovir disoproxil fumarate (Hepatitis-B, AIDS) requires more vitamin D – Sept 2018
Vertebral fractures 9X more likely in HIV patients having low vitamin D – Dec 2017
HIV patients helped by monthly 120,000 IU of Vitamin D – RCT Oct 2017
Those with HIV who doubled their vitamin D levels reduced their chance of death by 47 percent – Oct 2013
A gut-friendly form of vitamin D should be used for those with HIV and gut problems
Alternately, just use 2X to 3X more vitamin D than for a person who has a good gut
3X more African girls and women have HIV than African males Washington Post Dec 2023
Note: Many women have lower vitamin D levels than men due to hormones and not being outdoors as much
In addition, dark-skinned women often avoid the sun due to a desire to have a lighter skin shade
| 543 visitors, last modified 12 Aug, 2024, |